Proteasome inhibition induces apoptosis in Primary human natural killer cells and suppresses nkp46-mediated cytotoxicity

Haematologica

Volumn 94, Issue 4, 2009, Pages 470-478

  Wang, Xiangling ^a,b   Ottosson, Astrid ^c   Ji, Chunyan ^b   Feng, Xiaoli ^a   Nordenskjöld, Magnus ^a   Henter, Jan Inge ^a   Fadeel, Bengt ^c   Zheng, Chengyun ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHANDONG UNIVERSITY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Bortezomib; Natural killer cells; Nk receptor

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE INHIBITOR; GLUTATHIONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR P46; PROPIDIUM IODIDE; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL SURVIVAL; CELLULAR IMMUNITY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG LABELING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; TUMOR CELL;

APOPTOSIS; BORONIC ACIDS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 66349096076     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13783     Document Type: Article

References (33)

1. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501-10.
2. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, Moretta A. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214:219-28.
3. Ciechanover A. The ubiquitin-pro- teasome proteolytic pathway. Cell 1994;79:13-21.
4. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
5. Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest 2007;25: 766-75.
6. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile tar- get for the treatment of solid tumours? Eur J Cancer 2007;43:1125-33.
7. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing lig- and: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006;66:7317-25.
8. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180:163-70.
9. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses X. Wang et al. essential immune functions of human CD4(+) T cells. Immunology 2008;124:234-46.
10. Blanco B, Perez-Simon JA, Sanchez- Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective deple- tion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-83.
11. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, et al. Effect of frequently used chemother- apeutic drugs on the cytotoxic activ- ity of human natural killer cells. Mol Cancer Ther 2007;6:644-54.
12. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Arico M, et al. Analysis of natural killer-cell func- tion in familial hemophagocytic lym- phohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the dis- ease. Blood 2006;108:2316-23.
13. Sun Y, Ottosson A, Pervaiz S, Fadeel B. Smac-mediated sensitization of human B-lymphoma cells to stau- rosporine- and lactacystin-triggered apoptosis is apoptosome-dependent. Leukemia 2007;21:1035-43.
14. Jayaraman S. Flow cytometric deter- mination of mitochondrial mem- brane potential changes during apop- tosis of T lymphocytic and pancreat- ic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-X-rosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). J Immunol Methods 2005;306:68-79.
15. Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL. NKp44 triggers NK cell activation through DAP12 associa- tion that is not influenced by a puta- tive cytoplasmic inhibitory sequence. J Immunol 2004;172:899-906.
16. Zheng C, Ostad M, Andersson M, Celsing F, Holm G, Sundblad A. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in mul- tiple myeloma. Br J Haematol 2002; 118:778-85.
17. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor borte- zomib induces apoptosis in mantle- cell lymphoma through generation of ROS and Noxa activation independ- ent of p53 status. Blood 2006; 107: 257-64.
18. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitu- tive NF-[.kappa] B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
19. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib- induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139:385-97.
20. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
21. Shen L, Au WY, Guo T, Wong KY, Wong ML, Tsuchiyama J, et al. Proteasome inhibitor bortezomib- induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical eval- uation. Blood 2007;110:469-70.
22. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactiva- tion, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91.
23. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 2004;23:255-9.
24. Verheyden S, Demanet C. NK cell receptors and their ligands in leu- kemia. Leukemia 2008;22:249-57.
25. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2- deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
26. Nishimura M, Mitsunaga S, Akaza T, Mitomi Y, Tadokoro K, Juji T. Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression. Immunology 1994;83:75-80.
27. Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, et al. The mechanisms controlling the recognition of tumor- and virus- infected cells by NKp46. Blood 2004; 103:664-72.
28. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007;110: 1906-15.
29. Shi J, Tricot GJ, Garg TK, Mala- viarachchi PA, Szmania SM, Kellum RE, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell- mediated lysis of myeloma. Blood 2008;111:1309-17.
30. Pascal V, Nathan NR, Claudio E, Siebenlist U, Anderson SK. NF-[.kappa] B p50/p65 affects the frequency of Ly49 gene expression by NK cells. J Immunol 2007;179:1751-9.
31. Maseda D, Meister S, Neubert K, Herrmann M, Voll RE. Proteasome inhibition drastically but reversibly impairs murine lymphocyte develop- ment. Cell Death Differ 2008;15: 600-12.
32. Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dorken B, et al. Dendritic cell maturation stage deter- mines susceptibility to the protea- some inhibitor bortezomib. Hum Immunol 2007;68:147-55.
33. Straube C, Wehner R, Wendisch M, Bornhauser M, Bachmann M, Rieber EP, et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007;21: 1464-71.